{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:01:38Z","timestamp":1781881298312,"version":"3.54.5"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3-60065"],"award-info":[{"award-number":["J3-60065"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["P3-0449"],"award-info":[{"award-number":["P3-0449"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.biopha.2026.119079","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T23:14:17Z","timestamp":1771283657000},"page":"119079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["AKR1C inhibitors medroxyprogesterone acetate and mefenamic acid exhibit antitumor activity alone and combined with carboplatin in platinum-resistant high-grade serous ovarian cancer models"],"prefix":"10.1016","volume":"196","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-0071","authenticated-orcid":false,"given":"Nika","family":"Marolt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alja","family":"Zottel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Annibali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Amant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tea Lani\u0161nik","family":"Ri\u017ener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib2","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian Low-grade and High-grade Serous Carcinoma","volume":"16","author":"Vang","year":"2009","journal-title":"Adv. Anat. Pathol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119079_bib3","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.3390\/ijms22094409","article-title":"Mechanisms of High-Grade Serous Carcinogenesis in the Fallopian Tube and Ovary: Current Hypotheses, Etiologic Factors, and Molecular Alterations","volume":"22","author":"Otsuka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib4","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2026.119079_bib5","article-title":"Epithelial ovarian cancer: Review article","volume":"33","author":"Sambasivan","year":"2022","journal-title":"Cancer Treat. Res Commun."},{"issue":"20","key":"10.1016\/j.biopha.2026.119079_bib6","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","article-title":"Consensus on Molecular Subtypes of High-Grade Serous Ovarian Carcinoma","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119079_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair (Amst. )"},{"issue":"9332","key":"10.1016\/j.biopha.2026.119079_bib8","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib9","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1470-2045(12)70567-3","article-title":"Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial","volume":"14","author":"Stark","year":"2013","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/biom14050585","article-title":"Oncogenic Pathways and Targeted Therapies in Ovarian Cancer","volume":"14","author":"Lliberos","year":"2024","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib11","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030641","article-title":"The Poor Prognosis of Acquired Secondary Platinum Resistance in Ovarian Cancer Patients","volume":"16","author":"Elyashiv","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119079_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The Different Mechanisms of Cancer Drug Resistance: A Brief Review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174013","article-title":"Biology-driven therapy advances in high-grade serous ovarian cancer","volume":"134","author":"Wang","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib16","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and Functional Biology of Aldo-Keto Reductase Steroid-Transforming Enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib17","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1124\/pharmrev.120.000122","article-title":"Aldo-Keto Reductases and Cancer Drug Resistance","volume":"73","author":"Penning","year":"2021","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-05785-9","article-title":"AKR1C1\/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin","volume":"12","author":"Badmann","year":"2022","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib19","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1074\/jbc.M006655200","article-title":"The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene","volume":"276","author":"Burczynski","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2026.119079_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00280-007-0554-0","article-title":"Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells","volume":"61","author":"Chen","year":"2008","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2026.119079_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110676","article-title":"Emerging role of NRF2 in ROS-mediated tumor chemoresistance","volume":"131","author":"Xue","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119079_bib22","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.mce.2005.10.009","article-title":"AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer","volume":"248","author":"Rizner","year":"2006","journal-title":"Mol. Cell Endocrinol."},{"issue":"Pt 1","key":"10.1016\/j.biopha.2026.119079_bib23","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/bj3510067","article-title":"Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones","volume":"351","author":"Penning","year":"2000","journal-title":"Biochem J."},{"key":"10.1016\/j.biopha.2026.119079_bib24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.steroids.2013.10.012","article-title":"Role of aldo\u2013keto reductase family 1 (AKR1) enzymes in human steroid metabolism","volume":"79","author":"Ri\u017ener","year":"2014","journal-title":"Steroids"},{"issue":"12","key":"10.1016\/j.biopha.2026.119079_bib25","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bjc.2016.363","article-title":"Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer","volume":"115","author":"MacLeod","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2026.119079_bib26","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1093\/carcin\/bgp176","article-title":"Characterization of the cancer chemopreventive NRF2-dependent gene battery in human keratinocytes: demonstration that the KEAP1\u2013NRF2 pathway, and not the BACH1\u2013NRF2 pathway, controls cytoprotection against electrophiles as well as redox-cycling compounds","volume":"30","author":"MacLeod","year":"2009","journal-title":"Carcinogenesis"},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1021\/acs.chemrestox.6b00319","article-title":"Aldo-Keto Reductase Regulation by the Nrf2 System: Implications for Stress Response, Chemotherapy Drug Resistance, and Carcinogenesis","volume":"30","author":"Penning","year":"2017","journal-title":"Chem. Res Toxicol."},{"key":"10.1016\/j.biopha.2026.119079_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413239","article-title":"Nrf2 Signaling in Renal Cell Carcinoma: A Potential Candidate for the Development of Novel Therapeutic Strategies","author":"Schiavoni","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2026.119079_bib29","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1080\/14737140.2024.2438951","article-title":"NRF2\/KEAP1 signaling inhibitors in gynecologic cancers","volume":"24","author":"Fantone","year":"2024","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s11033-025-10878-5","article-title":"Effect of natural compounds on NRF2\/KEAP1 signaling in periodontitis: a potential use to prevent age-related disorders","volume":"52","author":"Tossetta","year":"2025","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12035-025-05517-w","article-title":"Nrf2\/Keap1 Signaling Axis in the Brain: Master Regulator of Oxidative Stress in Neurodegenerative and Psychiatric Disorders","volume":"63","author":"Goel","year":"2025","journal-title":"Mol. Neurobiol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119079_bib32","article-title":"Evaluation of Nrf2\/Keap1 Pathway in Patients with Migraine","volume":"61","author":"Ko\u00e7t\u00fcrk","year":"2025","journal-title":"Med. (Kaunas. )"},{"key":"10.1016\/j.biopha.2026.119079_bib33","series-title":"Reference Module in Neuroscience and Biobehavioral Psychology","article-title":"Estrogen in the Male: Nature, Sources, and Biological Effects\u2729","author":"Schweikert","year":"2019"},{"issue":"1-3","key":"10.1016\/j.biopha.2026.119079_bib34","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cbi.2010.12.012","article-title":"Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3","volume":"191","author":"Berani\u010d","year":"2011","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.biopha.2026.119079_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0009-2797(02)00206-5","article-title":"Selective and potent inhibitors of human 20\u03b1-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone","volume":"143-144","author":"Higaki","year":"2003","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.biopha.2026.119079_bib36","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/bj3130373","article-title":"Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells","volume":"313","author":"Hara","year":"1996","journal-title":"Biochem J."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib37","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1124\/jpet.105.091587","article-title":"Tibolone Metabolism in Human Liver Is Catalyzed by 3\u03b1\/3\u03b2-Hydroxysteroid Dehydrogenase Activities of the Four Isoforms of the Aldo-Keto Reductase (AKR)1C Subfamily","volume":"316","author":"Steckelbroeck","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib38","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1021\/jm201547v","article-title":"Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17\u03b2-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships","volume":"55","author":"Adeniji","year":"2012","journal-title":"J. Med Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119079_bib39","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1016\/j.bmcl.2012.03.085","article-title":"Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer","volume":"22","author":"Chen","year":"2012","journal-title":"Bioorg. Med Chem. Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib40","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1124\/mol.104.006569","article-title":"Development of nonsteroidal anti-inflammatory drug analogs and steroid carboxylates selective for human aldo-keto reductase isoforms: potential antineoplastic agents that work independently of cyclooxygenase isozymes","volume":"67","author":"Bauman","year":"2005","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119079_bib41","doi-asserted-by":"crossref","DOI":"10.1172\/JCI65833","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","author":"Verhaak","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"269","key":"10.1016\/j.biopha.2026.119079_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib43","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119079_bib44","unstructured":"R Studio Team. RStudio: Integrated Development Environment for R. 2016."},{"issue":"6","key":"10.1016\/j.biopha.2026.119079_bib45","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/2041-210X.13384","article-title":"metan: An R package for multi-environment trial analysis","volume":"11","author":"Olivoto","year":"2020","journal-title":"Methods Ecol. Evol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119079_bib46","doi-asserted-by":"crossref","DOI":"10.2196\/27633","article-title":"Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation","volume":"23","author":"L\u00e1nczky","year":"2021","journal-title":"J. Med Internet Res"},{"issue":"7","key":"10.1016\/j.biopha.2026.119079_bib47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/bjc.1997.471","article-title":"Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20","volume":"76","author":"Yanagibashi","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib48","first-page":"850","article-title":"Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines","volume":"57","author":"Johnson","year":"1997","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.biopha.2026.119079_bib49","first-page":"1197","article-title":"Biological characterization including sensitivity to mitomycin C of cultured human ovarian cancers (author's transl)]","volume":"33","author":"Motoyama","year":"1981","journal-title":"Nihon Sanka Fujinka Gakkai Zasshi"},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ijc.2910530415","article-title":"Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics","volume":"53","author":"van den Berg-Bakker","year":"1993","journal-title":"Int J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib51","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1158\/0008-5472.CAN-03-2928","article-title":"Tumor Necrosis Factor-\u03b1-Induced Matrix Proteolytic Enzyme Production and Basement Membrane Remodeling by Human Ovarian Surface Epithelial Cells: Molecular Basis Linking Ovulation and Cancer Risk","volume":"64","author":"Yang","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2026.119079_bib52","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.3389\/fmolb.2021.743403","article-title":"In the Model Cell Lines of Moderately and Poorly Differentiated Endometrial Carcinoma, Estrogens Can Be Formed via the Sulfatase Pathway","volume":"8","author":"Pavli\u010d","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2026.119079_bib53","article-title":"Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance","volume":"177","author":"Marolt","year":"2024","journal-title":"Biomed. amp Pharmacother."},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib54","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.biopha.2026.119079_bib55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cbi.2014.11.012","article-title":"Important roles of the AKR1C2 and SRD5A1 enzymes in progesterone metabolism in endometrial cancer model cell lines","volume":"234","author":"Sinreih","year":"2015","journal-title":"Chem. Biol. Interact."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119079_bib56","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.mce.2006.08.001","article-title":"Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1","volume":"259","author":"Brozic","year":"2006","journal-title":"Mol. Cell Endocrinol."},{"issue":"13-14","key":"10.1016\/j.biopha.2026.119079_bib57","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.steroids.2004.09.014","article-title":"Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase\/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate","volume":"69","author":"Lin","year":"2004","journal-title":"Steroids"},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib58","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2026.119079_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103910","article-title":"173P NRF2 levels in high grade serous ovarian cancer: Characterization and treatment","volume":"9","author":"Toma","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2026.119079_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118278","article-title":"Exploring the role of estrogens and steroid sulfatase inhibition in platinum resistance, proliferation, migration, and cell death in high-grade serous ovarian cancer cells","volume":"189","author":"Marolt","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"22","key":"10.1016\/j.biopha.2026.119079_bib61","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1016\/j.febslet.2010.10.046","article-title":"Secondary necrosis: the natural outcome of the complete apoptotic program","volume":"584","author":"Silva","year":"2010","journal-title":"FEBS Lett."},{"issue":"7","key":"10.1016\/j.biopha.2026.119079_bib62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1177\/1087057114532352","article-title":"The Resazurin Reduction Assay Can Distinguish Cytotoxic from Cytostatic Compounds in Spheroid Screening Assays","volume":"19","author":"Walzl","year":"2014","journal-title":"SLAS Discov."},{"key":"10.1016\/j.biopha.2026.119079_bib63","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.mex.2018.07.011","article-title":"Optimized alamarBlue assay protocol for drug dose-response determination of 3D tumor spheroids","volume":"5","author":"Eilenberger","year":"2018","journal-title":"MethodsX"},{"issue":"17","key":"10.1016\/j.biopha.2026.119079_bib64","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.1074\/jbc.M112028200","article-title":"Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells","volume":"277","author":"Deng","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib65","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s00280-004-0815-0","article-title":"Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase","volume":"54","author":"Deng","year":"2004","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2026.119079_bib66","doi-asserted-by":"crossref","first-page":"7673","DOI":"10.2147\/CMAR.S210004","article-title":"Correlation of NRF2 and progesterone receptor and its effects on ovarian cancer biology","volume":"11","author":"Czogalla","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib67","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/IGC.0000000000000908","article-title":"Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival","volume":"27","author":"Cho","year":"2017","journal-title":"Int J. Gynecol. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2026.119079_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123856","article-title":"High Expression of NRF2 Is Associated with Increased Tumor-Infiltrating Lymphocytes and Cancer Immunity in ER-Positive\/HER2-Negative Breast Cancer","volume":"12","author":"Oshi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010112","article-title":"Interaction of ER\u03b1 and NRF2 Impacts Survival in Ovarian Cancer Patients","volume":"20","author":"Czogalla","year":"2018","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119079_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1184079","article-title":"Nrf2 signaling pathway: current status and potential therapeutic targetable role in human cancers","volume":"13","author":"Lin","year":"2023","journal-title":"Front Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib71","article-title":"Role of NRF2 in Ovarian Cancer","volume":"11","author":"Tossetta","year":"2022","journal-title":"Antioxid. (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib72","doi-asserted-by":"crossref","DOI":"10.1038\/srep34625","article-title":"Aldo-keto reductase 1C1 induced by interleukin-1\u03b2 mediates the invasive potential and drug resistance of metastatic bladder cancer cells","volume":"6","author":"Matsumoto","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119079_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101421","article-title":"AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1\u03b1 and metabolic reprogramming","volume":"20","author":"Chang","year":"2022","journal-title":"Transl. Oncol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119079_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gene.2010.03.006","article-title":"The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene","volume":"459","author":"Pallai","year":"2010","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib75","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.bcp.2007.08.034","article-title":"Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: Role in the cell cycle and apoptosis","volume":"75","author":"Selga","year":"2008","journal-title":"Biochem. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2026.119079_bib76","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2000::AID-CNCR4>3.0.CO;2-B","article-title":"Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation","volume":"88","author":"Abe","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2026.119079_bib77","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.5530\/ijper.20250489","article-title":"Caspase Activation, Upregulation of Bax and P53, Downregulation of Bcl-2 and Enhanced Generation of Reactive Oxygen Species Mediate the Anti-proliferative and Anti-migratory Activity of Mefenamic Acid in Breast Cancer Cells","volume":"59","author":"AlZharani","year":"2025","journal-title":"Indian J. Pharm. Educ. Res."},{"key":"10.1016\/j.biopha.2026.119079_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.110931","article-title":"Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model","volume":"393","author":"Ye","year":"2024","journal-title":"Chem. Biol. Inter."},{"issue":"4","key":"10.1016\/j.biopha.2026.119079_bib79","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3892\/or.2017.5480","article-title":"Mefenamic acid enhances anticancer drug sensitivity via inhibition of aldo-keto reductase 1C enzyme activity","volume":"37","author":"Shiiba","year":"2017","journal-title":"Oncol. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib80","first-page":"252","article-title":"Clinical implication of medroxyprogesterone acetate against advanced ovarian carcinoma: a pilot study","volume":"29","author":"Niwa","year":"2008","journal-title":"Eur. J. Gynaecol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib81","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3892\/or.2014.3651","article-title":"MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer","volume":"33","author":"Wang","year":"2015","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2026.119079_bib82","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0002790","article-title":"Extra-Nuclear Signaling of Progesterone Receptor to Breast Cancer Cell Movement and Invasion through the Actin Cytoskeleton","volume":"3","author":"Fu","year":"2008","journal-title":"PLOS ONE"},{"issue":"6","key":"10.1016\/j.biopha.2026.119079_bib83","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065278","article-title":"Dialog beyond the Grave: Necrosis in the Tumor Microenvironment and Its Contribution to Tumor Growth","volume":"24","author":"Zapletal","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib84","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000444941","article-title":"Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment","volume":"43","author":"Lotfi","year":"2016","journal-title":"Transfus. Med Hemother"},{"key":"10.1016\/j.biopha.2026.119079_bib85","doi-asserted-by":"crossref","DOI":"10.1177\/10732748211066311","article-title":"From Apoptosis to Necroptosis: The Death Wishes to Cancer","volume":"28","author":"Meng","year":"2021","journal-title":"Cancer Control"},{"key":"10.1016\/j.biopha.2026.119079_bib86","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2147\/CMAR.S163747","article-title":"Comparison of NSAIDs activity in COX-2 expressing and non-expressing 2D and 3D pancreatic cancer cell cultures","volume":"10","author":"\u010ceponyt\u0117","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"20","key":"10.1016\/j.biopha.2026.119079_bib87","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/j.lfs.2004.04.042","article-title":"Mefenamic acid-induced apoptosis in human liver cancer cell-lines through caspase-3 pathway","volume":"75","author":"Woo","year":"2004","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119079_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ph8010062","article-title":"Hitting the Bull\u2019s-Eye in Metastatic Cancers\u2014NSAIDs Elevate ROS in Mitochondria, Inducing Malignant Cell Death","author":"Ralph","year":"2015","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib89","article-title":"The role of non-genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death","volume":"7","author":"Koyanagi","year":"2024","journal-title":"Cancer Rep (Hoboken)"},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib90","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s12032-021-01618-3","article-title":"Mefenamic acid as a promising therapeutic medicine against colon cancer in tumor-bearing mice","volume":"39","author":"Seyyedi","year":"2022","journal-title":"Med Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib91","doi-asserted-by":"crossref","DOI":"10.1152\/ajprenal.00062.2005","article-title":"Medroxyprogesterone acetate binds the glucocorticoid receptor to stimulate \u03b1-ENaC and sgk1 expression in renal collecting duct epithelia","volume":"290","author":"Thomas","year":"2006","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"1-2","key":"10.1016\/j.biopha.2026.119079_bib92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0303-7207(99)00109-4","article-title":"Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells","volume":"154","author":"Bentel","year":"1999","journal-title":"Mol. Cell Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119079_bib93","first-page":"1217","article-title":"Effects of high-dose medroxyprogesterone acetate and various other steroid hormones on plasma membrane lipid mobility in CAMA-1 mammary cancer cells","volume":"7","author":"Van B\u00f6mmel","year":"1987","journal-title":"Anticancer Res"},{"issue":"29","key":"10.1016\/j.biopha.2026.119079_bib94","doi-asserted-by":"crossref","first-page":"15069","DOI":"10.1074\/jbc.M116.725713","article-title":"Substrate-selective Inhibition of Cyclooxygeanse-2 by Fenamic Acid Derivatives Is Dependent on Peroxide Tone","volume":"291","author":"Orlando","year":"2016","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.biopha.2026.119079_bib95","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043965","article-title":"Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3","volume":"7","author":"Flanagan","year":"2012","journal-title":"PLOS ONE"},{"issue":"18","key":"10.1016\/j.biopha.2026.119079_bib96","first-page":"5084","article-title":"Effect of medroxyprogesterone acetate on proliferation and cell cycle kinetics of human mammary carcinoma cells","volume":"48","author":"Sutherland","year":"1988","journal-title":"Cancer Res"},{"issue":"9_Supplement","key":"10.1016\/j.biopha.2026.119079_bib97","first-page":"1103","article-title":"High dose medroxyprogesterone acetate (MPA) has anti-angiogenic properties","volume":"68","author":"Marshall","year":"2008","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib98","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1530\/eje.0.1380574","article-title":"Effect of medroxyprogesterone acetate on sex hormone-binding globulin mRNA expression in the human endometrial cancer cell line Ishikawa","volume":"138","author":"Misao","year":"1998","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib99","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/00016347909154923","article-title":"Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma","volume":"58","author":"Laatikainen","year":"1979","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.biopha.2026.119079_bib100","unstructured":"Administration USFaD. Provera (medroxyprogesterone acetate) tablets: Prescribing Information. 2018 [cited 2026 14\/01\/2026]; Available from: chrome-extension:\/\/efaidnbmnnnibpcajpcglclefindmkaj\/\u3008https:\/\/www.api.drugx.com.bd\/public\/upload\/innovatorsMonograph\/medroxyprogesterone-acetate-tablet-prescribing-information.pdf?utm_source=chatgpt.com\u3009."},{"key":"10.1016\/j.biopha.2026.119079_bib101","unstructured":"Agency E.M. Medroxyprogesterone acetate \u2013 Direct Healthcare Professional Communication (DHPC). 2024 [cited 2026 14\/01\/2026]; Available from: \u3008https:\/\/www.ema.europa.eu\/en\/medicines\/dhpc\/medroxyprogesterone-acetate\u3009."},{"issue":"5","key":"10.1016\/j.biopha.2026.119079_bib102","first-page":"431","article-title":"[Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate]","volume":"80","author":"Etienne","year":"1993","journal-title":"Bull. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119079_bib103","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00292875","article-title":"The pharmacokinetics of high-dose medroxyprogesterone acetate (MPA) in the therapy of advanced breast cancer","volume":"8","author":"Blossey","year":"1982","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119079_bib104","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000333558","article-title":"In vitro\/in vivo correlation of fast release mephenamic acid microspheres in humans","volume":"21","author":"Etman","year":"2012","journal-title":"Med Princ. Pr."},{"issue":"9","key":"10.1016\/j.biopha.2026.119079_bib105","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/jps.2600750914","article-title":"Bioavailability of mefenamic acid: influence of food and water intake","volume":"75","author":"Hamaguchi","year":"1986","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2026.119079_bib106","article-title":"Mefenamic Acid Poisoning Revisited: Central Nervous System Toxicity and Acute Kidney Injury","volume":"17","author":"Inoue","year":"2025","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.biopha.2026.119079_bib107","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/cpt.1846","article-title":"Does In Vitro Potency Predict Clinically Efficacious Concentrations?","volume":"108","author":"Jansson-L\u00f6fmark","year":"2020","journal-title":"Clin. Pharm. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2026.119079_bib108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008147","article-title":"Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia","volume":"4","author":"Khanim","year":"2009","journal-title":"PLoS One"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226001113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T14:48:02Z","timestamp":1781880482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226001113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":108,"alternative-id":["S0753332226001113"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119079","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AKR1C inhibitors medroxyprogesterone acetate and mefenamic acid exhibit antitumor activity alone and combined with carboplatin in platinum-resistant high-grade serous ovarian cancer models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119079"}}